Overview
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for the CDC-funded coordinating center of the influenza and other respiratory virus vaccine effectiveness network. This work provides national estimates for influenza and other respiratory virus vaccine effectiveness in persons presenting with respiratory illness in the ambulatory setting.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine effectiveness, vaccine coverage, prevention and treatment of infectious diseases.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial.
Journal Article Vaccine · February 6, 2026 BACKGROUND: A U.S. multisite trial was conducted and explored whether blunting of mRNA COVID-19 vaccine immunogenicity occurred when administered simultaneously with influenza vaccine. METHODS: Persons ≥5 years of age received either quadrivalent inactivat ... Full text Link to item CiteEstimating influenza transmission parameters: Comparing two study designs, 2023-2024.
Journal Article Epidemics · January 12, 2026 Household studies play a critical role in estimating influenza transmission parameters, which are essential for real-time modeling of epidemic and pandemic dynamics to inform influenza control strategies. We compared two approaches for estimating household ... Full text Link to item CiteA neutralizing human antibody induces movement of the HCoV-229E receptor binding domain.
Journal Article Commun Biol · December 31, 2025 HCoV-229E is an endemic Alphacoronavirus that typically causes common cold-like disease in most healthy adults, but can also cause severe respiratory disease in the very young and the elderly. Although the virus was discovered over sixty years ago and unde ... Full text Link to item CiteRecent Grants
CIVICS Component C - Option 13B.1 Biorepository
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2026 - 2030Duke University Maternal-Fetal Medicine Units (MFMU) Network Clinical Center
ResearchCollaborating Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2023 - 2030CIVICS Component C - Option 16 EA - COBRA
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2029View All Grants